This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
American Heart Association Scientific Statement DALLAS, July 26, 2021 — Genomic studies have produced advances in how to calculate and reduce heart-disease risk, however, the benefits don’t necessarily apply to people from historically marginalized racial and ethnic groups and Indigenous populations.
Associated collaboration with the New York Genome Center to expand patient access to advanced genomic technologies Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc.
Phosphorus, a leading preventative genomics company, has developed the first comprehensive preventative genetic test for consumers. Like other consumer genomic tests, the Phosphorus GeneCompass test also involves the collection of saliva samples that consumers send to the Phosphorus lab located in Secaucus, NJ for analysis.
Circulation: Genomic and Precision Medicine Journal Report DALLAS, July 13, 2021 — Sharing the results of genetic testing for cardiomyopathy in adolescents ages 13-18 does not appear to cause emotional harm to families or adversely impact family function or dynamics, according to new research published today in Circulation: Genomic and Precision (..)
Genomic analysis by researchers from the UK and the Netherlands has found links between hypertensive disorders in pregnancy (HDPs) and a higher risk of coronary artery disease and stroke.
In their paper published in the journal Science, the group describes using the gene editing system to modify two bases in the mouse genome to prevent hyperactivation of a protein that can lead to heart disease.
Identifies people at high risk of heart attack despite average LDL cholesterol levels Rome, Italy, March 8, 2021 – Allelica, a leading genomics software company specialising in developing polygenic risk scores (PRS) for personalised medicine, today announced publication of a study in Circulation (Vol.
28, 2020 — There may be a positive causal relationship between elevated birth weight and risk for future atrial fibrillation in adulthood, according to a study presented at the annual Great Wall International Congress of Cardiology, held virtually from Oct. The genome-wide association study included 321,223 individuals.
In people with a single-gene variant that puts them at high risk for heart disease, breast cancer, or colorectal cancer, the rest of the genome can alter that risk Life can change dramatically when someone learns they are genetically predisposed to a disease, such as a condition called familial hypercholesterolemia, where a mutated gene can […]. (..)
AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases.
Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company’s work on preventing heart disease with genome editing. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.
This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. Dr. Januzzi describes a “biomarker Phase II,” which involves applying an unbiased inductive approach using omics-based approaches, such as proteomics, metabolomics, genomics and transcriptomics, to identify plausible drug-marker pairs.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content